ENSC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

500.00K

-61.65%

-1.260

-56.55%

0.00

-100%

-0.820

-41.01%

0.00

-100%

-0.460

-41.77%

Estimates Revision

The market is revising No Change the revenue expectations for Ensysce Biosciences, Inc. (ENSC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -56.22%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-56.22%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Ensysce Biosciences Inc (ENSC.O) is -0.32, compared to its 5-year average forward P/E of -2.20. For a more detailed relative valuation and DCF analysis to assess Ensysce Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.20

Current PE

-0.32

Overvalued PE

1.40

Undervalued PE

-5.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.28

Current EV/EBITDA

-0.12

Overvalued EV/EBITDA

0.27

Undervalued EV/EBITDA

-0.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

622.50

Current PS

6.83

Overvalued PS

2641.88

Undervalued PS

-1396.89

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ENSC News & Events

Events Timeline

No data

News

9.0

2025-12-12Globenewswire

Ensysce Initiates PF614 Phase 3 Enrollment, Advancing Towards Commercialization

3.5

2025-12-12Newsfilter

Ensysce Initiates PF614 Phase 3 Enrollment, Advancing Towards Commercialization

3.5

2025-11-24Newsfilter

Ensysce Secures FDA Approval for PF614 Commercial Production Pathway

People Also Watch

Frequently Asked Questions

What is Ensysce Biosciences Inc (ENSC) stock price today?

The current price of ENSC is 1.02 USD — it has decreased -3.77 % in the last trading day.

What is Ensysce Biosciences Inc (ENSC)'s business?

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

What is the price predicton of ENSC Stock?

Wall Street analysts forecast ENSC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENSC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Ensysce Biosciences Inc (ENSC)'s revenue for the last quarter?

Ensysce Biosciences Inc revenue for the last quarter amounts to 493.10K USD, decreased -85.58 % YoY.

What is Ensysce Biosciences Inc (ENSC)'s earnings per share (EPS) for the last quarter?

Ensysce Biosciences Inc. EPS for the last quarter amounts to -1.29 USD, decreased -229.00 % YoY.

What changes have occurred in the market's expectations for Ensysce Biosciences Inc (ENSC)'s fundamentals?

How many employees does Ensysce Biosciences Inc (ENSC). have?

Ensysce Biosciences Inc (ENSC) has 7 emplpoyees as of January 10 2026.

What is Ensysce Biosciences Inc (ENSC) market cap?

Today ENSC has the market capitalization of 3.70M USD.